Guidelines
Belzutifan (WELIREG) is included in certain NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1,2
NCCN Guidelines® for Kidney Cancer (confirmed hereditary VHL-associated RCC)
Belzutifan (WELIREG) is the only preferred systemic therapy option (category 2A) for patients with VHL-associated RCC not requiring immediate surgery.1
NCCN Guidelines for CNS Cancers (VHL-associated CNS hemangioblastomas)
Belzutifan (WELIREG) is the only systemic therapy option identified as useful in certain circumstances (category 2A) for patients with VHL-associated CNS hemangioblastomas not requiring immediate surgery.2